TY  - JOUR
AU  - Adolph, Jonas E
AU  - Fleischhack, Gudrun
AU  - Gaab, Christine
AU  - Mikasch, Ruth
AU  - Mynarek, Martin
AU  - Rutkowski, Stefan
AU  - Schüller, Ulrich
AU  - Pfister, Stefan M
AU  - Pajtler, Kristian
AU  - Milde, Till
AU  - Witt, Olaf
AU  - Bison, Brigitte
AU  - Warmuth-Metz, Monika
AU  - Kortmann, Rolf-Dieter
AU  - Dietzsch, Stefan
AU  - Pietsch, Torsten
AU  - Timmermann, Beate
AU  - Tippelt, Stephan
TI  - Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies.
JO  - Journal of neuro-oncology
VL  - 155
IS  - 2
SN  - 1573-7373
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - DKFZ-2021-02286
SP  - 193-202
PY  - 2021
N1  - 2021 Nov;155(2):193-202
AB  - Survival in recurrent ependymoma (EPN) depends mainly on the extent of resection achieved. When complete resection is not feasible, chemotherapy is often used to extend progression-free and overall survival. However, no consistent effect of chemotherapy on survival has been found in patients with recurrent EPN.Systemic chemotherapeutic treatment of 138 patients enrolled in the German HIT-REZ-studies was analyzed. Survival depending on the use of chemotherapy, disease-stabilization rates (RR), duration of response (DOR) and time to progression (TTP) were estimated.Median age at first recurrence was 7.6 years (IQR: 4.0-13.6). At first recurrence, median PFS and OS were 15.3 (CI 13.3-20.0) and 36.9 months (CI 29.7-53.4), respectively. The Hazard Ratio for the use of chemotherapy in local recurrences in a time-dependent Cox-regression analysis was 0.99 (CI 0.74-1.33). Evaluable responses for 140 applied chemotherapies were analyzed, of which sirolimus showed the best RR (50
KW  - Chemotherapy (Other)
KW  - Children (Other)
KW  - Ependymoma (Other)
KW  - Recurrence (Other)
KW  - Sirolimus (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34657224
DO  - DOI:10.1007/s11060-021-03867-8
UR  - https://inrepo02.dkfz.de/record/177080
ER  -